Hibiscus mutabilis flower flavonoid compound and preparation method and use thereof
A flavonoid compound from Hibiscus mutabilis flowers addresses the need for safer anti-inflammatory treatments for bacterial vaginitis by effectively reducing inflammation markers and improving vaginal health in rat models.
Patent Information
- Application Number
- CN202411407549.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-10
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-10-10
AI Technical Summary
Current treatments for bacterial vaginitis lack effective and safe alternatives that can significantly reduce inflammation and restore vaginal health without the side effects associated with conventional antibiotics.
A flavonoid compound extracted from Hibiscus mutabilis flowers, specifically 8-(1-(3,4-dihydroxyphenyl)ethyl)-3,3',5,7-tetrahydroxy-4'-methoxyl flavone, is prepared through a multi-step process involving extraction, column chromatography, and purification, demonstrating anti-inflammatory activity in vitro and in vivo models.
The flavonoid compound effectively reduces inflammation markers in macrophages and alleviates symptoms of bacterial vaginitis in rats, showing comparable efficacy to metronidazole with reduced side effects.
Smart Images

Figure CN118908928B_ABST
Abstract
Description
Technical Field
[0001] The invention provides a hibiscus flower flavonoid compound and a preparation method and application thereof, belonging to the field of medicines. Background Art
[0002] Hibiscus Hibiscus mutabilis. L is a plant of the genus Hibiscus in the Malvaceae family. It is native to Hunan, my country and is widely distributed in the Yangtze River and Yellow River basins. According to research, the cultivation history of Hibiscus mutabilis in my country has been as long as 3,000 years. There are many varieties, and the common varieties are red hibiscus, pink hibiscus, white hibiscus, drunken hibiscus, mandarin duck hibiscus, colorful hibiscus, seven-star hibiscus, etc. Hibiscus mutabilis is not only a beautiful ornamental plant, but also has good medicinal value. Its flowers, leaves, and roots can be used as medicine. The 2020 edition of the "Chinese Pharmacopoeia" records that Hibiscus mutabilis leaves can be used to cool blood, detoxify, reduce swelling, relieve pain, treat snake entanglement, burns, red and swollen eyes, and injuries from falls. Hibiscus mutabilis flowers have the effects of clearing the lungs and cooling blood, dissipating heat and detoxifying, reducing swelling and discharging pus, and can be used to treat scrofula, intestinal carbuncle, leucorrhea, etc. At present, it is included in the processing specifications of Chinese herbal medicines in Shanghai, Tianjin, Jiangxi, Guangdong and other places. The Compendium of Materia Medica records that "Hibiscus mutabilis has both flowers and leaves, which are neither cold nor hot, slightly spicy, and slippery and sticky. It is very effective in treating carbuncle and swelling". The Chinese Materia Medica records that the root of Hibiscus mutabilis is cool, spicy, and slightly bitter, and can clear away heat and detoxify, cool blood and reduce swelling. It is mainly used to treat carbuncle and swelling, lung abscess, cough and asthma, red and swollen eyes, and leucorrhea in women. Modern pharmacological studies have shown that Hibiscus mutabilis also has antioxidant, antiviral, antibacterial, anti-inflammatory, and protective activities against renal ischemia-reperfusion injury. In addition, Hibiscus mutabilis is also widely used as a raw material or additive for cosmetics and food.
[0003] Hibiscus mutabilis has the effects of clearing away heat and detoxifying, reducing swelling and draining pus, cooling blood and stopping bleeding. Its clinical prescriptions are recorded in many books. "Miraculous Prescriptions" mentions that hibiscus flowers are ground into powder and applied to treat moxibustion sores that do not heal; "Women's Prescriptions" records that frost-resistant flowers and lotus shells are divided into equal parts and ground into powder. Two coins are taken each time with rice to treat continuous menstrual bleeding. Fujian's "Folk Practical Herbs" mentions that fresh hibiscus flowers and winter honey are two taels. Mashed and applied, changed two to three times a day, can be used to treat snake head carbuncle and snake venom. "Shanghai Commonly Used Chinese Herbal Medicines" records that hibiscus flowers are three to one tael, decocted and taken to treat vomiting blood, uterine bleeding, fire eyes, sores, lung abscesses, etc. "Hunan Pharmacopoeia" records that hibiscus flowers, leaves, and moutan bark are decocted and washed to treat carbuncle swelling and poison; hibiscus flowers are dried, ground into powder, and mixed with sesame oil to treat water scalds. "Chongqing Herbs" mentions that 2 to 4 liang of hibiscus flowers, 1 liang of deer mouth grass, and 2 liang of brown sugar can be stewed with pig heart and lungs. Salt can also be added if there is no sugar. It is used to treat consumptive cough.
[0004] Hibiscus mutabilis contains rich chemical components, including flavonoids and their glycosides, volatile oils, phenols, steroidal compounds, amino acids, tannins, sugars, inorganic compounds, etc. Among them, the largest and most important active ingredients are flavonoids and their glycoside compounds. According to statistics, 73 flavonoid compounds have been isolated and identified from Hibiscus mutabilis so far, including 48 flavonoid components isolated and identified from Hibiscus mutabilis leaves and 36 flavonoid components isolated and identified from Hibiscus mutabilis flowers. Application number 202210467131.5, invention name: compound hibiscus hibiscus, preparation method and use thereof, the present invention belongs to the field of medicine and health care products, and specifically relates to a new compound hibiscus hibiscus hibiscus, preparation method and use thereof. The invented compound was extracted and isolated from Hibiscus mutabilus flowers for the first time. Its chemical name is 1”-methoxy-3,5,7,4',3”',4”'-hexahydroxyflavone and named as Hibiscus mutabilfloin. Its English name is Mutabilfloin. The compound has multi-purpose application prospects such as anti-inflammatory, but the patent only discloses the anti-inflammatory effect and does not disclose the diseases to be treated. Summary of the invention
[0005] The invention provides a new flavonoid compound, and also provides a preparation method and application of the flavonoid compound.
[0006] The present invention provides a flavonoid compound, the structural formula of which is shown in Formula I:
[0007] .
[0008] The invention also provides use of the flavonoid compound in preparing anti-inflammatory drugs.
[0009] Wherein, the medicine is a medicine for treating vaginitis.
[0010] More preferably, the drug is a drug for treating bacterial vaginitis.
[0011] The present invention also provides the flavonoid compound used in the hibiscus plant of the Malvaceae family Hibiscus mutabilis. Application of dried flowers or extracts of L.
[0012] The flavonoid compound of the present invention is derived from Hibiscus mume Hibiscus mutabilis. The dried flowers of L are used as raw materials, extracted, separated and purified.
[0013] The raw material used is dried hibiscus flowers, that is, the flowers that have just opened or the buds that are about to open are picked during the flowering period and then dried in the sun or in an oven.
[0014] The present invention also provides a method for preparing the flavonoid compound, which comprises the following steps:
[0015] a. Extraction:
[0016] Take hibiscus flowers, grind them into powder, and extract them under reflux with 90% ethanol solution as solvent; evaporate the extract under reduced pressure to dryness to obtain dry extract; disperse and suspend the dry extract in ten times the amount of water, and then extract with equal volumes of petroleum ether, ethyl acetate and n-butanol for 3 times in sequence, evaporate the solvent to obtain three parts of extracts of petroleum ether, ethyl acetate and n-butanol respectively;
[0017] b. Take the ethyl acetate extract of step a, and separate it by column chromatography using a 100-200 mesh silica gel column, using petroleum ether-ethyl acetate as the elution solvent, and eluting according to the gradient of 20:1, 8:1, 5:1, 2:1, 1:1, 1:2, 1:4, 1:10, 0:100, and collect the fractions, and receive 127 bottles in total; among them, 1-15 is Fr.A, 26-37 is Fr.B, 38-52 is Fr.C, 53-68 is Fr.D, 69-90 is Fr.E, 91-109 is Fr.F, and 110-127 is Fr.G;
[0018] c. Fr.D was collected and further separated by ODS C18 medium pressure column. The eluent was methanol-water system. Gradient elution was performed according to 5:95, 10:90, 15:85, 20:80, 25:75, 30:70, 35:65, 40:60, 45:55, 50:50, 55:45, 60:40, 65:35, 70:30, 90:10, 100:0. A total of 119 bottles of fractions were collected; among them, 1-10 was Fr.D 1, 11-13 was Fr.D 2, 14-16 was Fr.D 3, 17-20 was Fr.D 4, 21-24 was Fr.D 5, 25-26 was Fr.D 6, 27-32 is Fr.D 7, 33-38 is Fr.D 8, 39-45 is Fr.D 9, 46-48 is Fr.D 10, 49-56 is Fr.D 11, 57-68 is Fr.D 12, 69-79 is Fr.D 13, 80-96 is Fr.D 14, 97-108 is Fr.D 15, 109-119 is Fr.D 16; Fr.D5 is separated and purified by preparative liquid chromatography using 35% acetonitrile aqueous solution as the mobile phase to obtain the compound shown in formula I.
[0019] The beneficial effects of the present invention are:
[0020] The present invention adopts traditional extraction, separation and purification technology to obtain a new compound of formula I, and confirms that it has significant anti-inflammatory activity through anti-inflammatory activity experiments and protein immunoblotting, and confirms its anti-inflammatory pathway; efficacy experiments prove that the flavonoid compound of the present invention is used to treat vaginitis, has obvious efficacy, and can achieve obvious efficacy at a medium dose, providing a new choice for clinical practice. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 This is a flow chart of the extraction and separation of flavonoid compounds of the present invention;
[0022] Figure 2 The effect of the compound of formula I on the proliferation of RAW264.7 cells (Note: ns, no significant difference compared with the blank group; the blank group was used as a reference ***P<0.001);
[0023] Figure 3 The effect of the compound of formula I on the NO release of RAW264.7 cells (Note: the blank group is used as a reference ### P<0.001; with the model group as reference **P<0.01, ***P<0.001, "1" in the figure refers to the compound of formula I);
[0024] Figure 4 The effect of the compound of formula I on the release of TNF-α and IL-6 in RAW264.7 cells (Note: the blank group is used as a reference, ### P<0.001; with the model group as the reference, ***P<0.001, **P<0.01, ns means no significant difference; blank a,b Indicates that the concentration is lower than the minimum detection limit, and "1" in the figure refers to the compound of formula I);
[0025] Figure 5 The effect of the compound of formula I on the expression levels of iNOS, COX-2, P65, p-P65 and other proteins in RAW264.7 cells stimulated by LPS (Note: Compared with the blank group, ### P<0.001; compared with the model group, ***P<0.001, **P<0.01; no mark indicates no significant difference). DETAILED DESCRIPTION
[0026] Example 1 Preparation of flavonoid compounds of the present invention
[0027] 1. Source and identification of medicinal materials
[0028] The hibiscus flower samples were collected from the hibiscus flower planting base in Chengdu, Sichuan Province. The flower samples are hibiscus flowers of the genus Hibiscus in the Malvaceae family. Hibiscus mutabilis Dried flowers of L.
[0029] 2. Extraction, separation and purification
[0030] 2.1. Extraction
[0031] Take 20 kg of hibiscus flowers, grind them into powder, and use 90% ethanol solution as solvent to reflux and extract 3 times, each time for 2 hours. The extract was evaporated to dryness under reduced pressure to obtain about 3.3 kg of dry extract. The dry extract was dispersed and suspended in ten times the amount of water, and then extracted 3 times with equal volumes of petroleum ether (PET), ethyl acetate (EtOAc), and n-butanol (nBuOH) in turn. The solvent was evaporated to obtain three parts of extracts, PET, EtOAc, and nBuOH, respectively. In this experiment, the EtOAc extract (90 g) was further separated.
[0032] 2.2. Separation and purification
[0033] Take about 80 g of EtOAc extract, use 100-200 mesh silica gel column for column chromatography separation, the elution solvent is petroleum ether-ethyl acetate, elution is carried out according to the gradient of 20:1, 8:1, 5:1, 2:1, 1:1, 1:2, 1:4, 1:10, 0:100, collect, and receive 127 bottles of fractions. After thin layer inspection and merging fractions, 7 components Fr.A~Fr.G are obtained. Among them, 1-15 is Fr.A, 26-37 is Fr.B, 38-52 is Fr.C, 53-68 is Fr.D, 69-90 is Fr.E, 91-109 is Fr.F, and 110-127 is Fr.G. Collect Fr.D for use; collect 12.64 g of fraction Fr.D. Fr.D was further separated using an ODS C18 medium-pressure column with a methanol-water system as the eluent. Gradient elution was performed at 5:95, 10:90, 15:85, 20:80, 25:75, 30:70, 35:65, 40:60, 45:55, 50:50, 55:45, 60:40, 65:35, 70:30, 90:10, and 100:0. A total of 119 bottles of fractions were collected. 1-10 is Fr.D 1, 11-13 is Fr.D 2, 14-16 is Fr.D 3, 17-20 is Fr.D 4, 21-24 is Fr.D 5, 25-26 is Fr.D 6, 27-32 is Fr.D 7, 33-38 is Fr.D 8, 39-45 is Fr.D 9, 46-48 is Fr.D 10, 49-56 is Fr.D 11, 57-68 is Fr.D 12, 69-79 is Fr.D 13, 80-96 is Fr.D 14, 97-108 is Fr.D15, 109-119 is Fr.D 16. Fr.D5 was separated and purified by semi-preparative liquid chromatography using 35% acetonitrile aqueous solution as the mobile phase for the compound of formula I. The separation process is shown below Figure 1 .
[0034] The structure is as formula Ⅰ, the chemical formula is C 24 H 20 O9.
[0035]
[0036] The chemical name of the compound of formula I is 8-(1-(3,4-dihydroxyphenyl)ethyl)-3,3',5,7-tetrahydroxy-4'-methoxyl flavone 。
[0037] The NMR data (600 MHz, CD3OH, J in Hz) of the compound of formula I of the present invention are shown in Table 1.
[0038] Table 1 NMR data of the compound of formula I of the present invention
[0039]
[0040] a) The measurement frequency is 600MHz; b) The measurement frequency is 150MHz.
[0041] The physical and chemical properties of the compound described by formula I of the present invention are: yellow powder, easily soluble in methanol.
[0042] Spectral data of the compound described in formula I of the present invention: -60 (c 0.05, MeOH), IR (KBr) vmax3432, 1601, 1555, 1516 cm -1 ; UV λ max 260, 380 nm; HRESIMS m / z 451.10 [MH] -; 1H-NMR (600 MHz, CD3OD) δ: 7.69 (1H, d, J =2.2 Hz, H-2'), 7.18 (1H, dd, J =8.2,2.2 Hz, H-6'), 6.93 (1H, d, J = 2.0 Hz, H-2'''), 6.80 (1H, d, J =8.2 Hz, H-5'), 6.79 (1H, dd, J = 8.2, 2.0 Hz, H-6'''), 6.69 (1H, d, J = 8.2 Hz, H-5'''), 6.29 (1H, s, H-6), 4.88 (1H, q, J =7.2 Hz, H-1''), 3.69 (3H, s, 4'-OCH3), 1.76 (3H, d, J =7.3 Hz, H-2''); 13C-NMR (151 MHz, CD3OD) δ: 148.52 (C-2), 136.97 (C-3), 177.67 (C-4), 160.45 (C-5), 99.17 (C-6), 163.10 (C-7), 112.46 (C-8), 155.67 (C-9), 104.97 (C-10), 124.24 (C-1'), 116.57 (C-2'), 146.13 (C-3'), 148.70 (C-4'), 56.26 (4'-OCH3), 116.09 (C-5'), 121.81 (C-6') ,33.95 (C-1''), 18.85 (C-2''), 138.33 (C-1''') , 112.02 (C-2'''), 145.34 (C-3'''), 148.62 (C-4''') , 115.87 (C-5'''), 120.73 (C-6''').
[0043] Optical rotation of the compound of formula I of the present invention -60 (c 0.05, methanol), from the infrared spectrum, we can observe 3432, 1601, 1555, 1516 cm -1 There is absorption at 260 nm, indicating that the compound contains hydroxyl, carbonyl and benzene rings. The UV spectrum shows that the compound has strong absorption at 260 and 380 nm. The LC-MS quasi-molecular ion peak is at m / z451.10 [MH] - appears at (calculated value is 451.11), unsaturation Ω = 15, and the molecular formula is determined to be C 24 H 20O9.
[0044] The compounds of formula I of the present invention 1 H-NMR spectrum showed that δ 7.69 (1H, d, J =2.2 Hz, H-2'), 6.80 (1H, d, J =8.2 Hz, H-5'), 7.18 (1H, dd, J =8.2, 2.2 Hz, H-6') were characteristic signals of 3', 4'-dioxy substituted flavonoids. 13 C NMR data and quercetin 13 C NMR data (Table 1) were compared to confirm that the flavonoid part of the molecule was quercetin. 1 In the H NMR spectrum, the hydrogen on the carbon (C-6) at δ 99.17 is a single peak, which indicates that there is a substitution at the C-8 position of the flavonoid part of the compound. In the HMBC spectrum, the hydrogen on the methyl carbon at δ 56.26 is remotely correlated with C-4', indicating that the hydroxyl hydrogen at the 4' position of the compound is replaced by a methyl group based on the structure of the quercetin parent nucleus. In addition to the aromatic carbon associated with quercetin, 13 The C NMR spectrum showed that the compound contained three oxygen-linked aromatic carbon atoms at δ 138.33, 145.34, and 148.62, and three non-oxygen-linked aromatic carbon atoms at δ 112.02, 115.87, and 120.73, which indicated the presence of another phenyl group in the molecule. 1 H- 1 The H-COSY spectrum shows that the hydrogens attached to the three carbons at δ 112.02, 115.87, and 120.73 are 6.93 (1H, d, J =2.0 Hz), 6.69 (1H, d, J =8.2 Hz), and 6.79 (1H, dd, J = 8.2,2.0 Hz), respectively. 1 The H NMR spectrum shows that the phenyl group is an ABX system substituent. 1 H NMR spectra and 1 H- 1The H COSY spectrum shows that a hydrogen at δ 4.88 is coupled to the methyl hydrogen at δ 1.76 to show a quartet (q), which indicates the presence of an ethyl group in the molecule. HSQC shows that the carbons at δ 33.95 and δ 18.85 are the carbons to which the hydrogens at δ 4.88 and δ 1.76 are connected, respectively. In addition, the carbon at δ 33.95 is a tertiary aliphatic carbon, indicating that the carbon is connected to two quaternary carbons. The HMBC spectrum shows that the hydrogen at δ 4.88 is remotely correlated with C-7, C-8, C-9, C-2''', and C-6'''. Combining all the above evidence, it is determined that the carbon at δ 33.95 is connected to the methyl, phenyl, and quercetin parent nucleus. The calculated unsaturation is 15, indicating that there is no ring structure in the molecule. In summary, the compound of formula I was determined to be 8-(1-(3,4-dihydroxyphenyl)ethyl)-3,3',5,7-tetrahydroxy-4'-methoxylflavone.
[0045] The beneficial effects of the present invention are demonstrated by pharmacodynamic tests as follows.
[0046] Test Example 1 Anti-inflammatory activity test of the compounds of the present invention
[0047] 1. Cell line culture
[0048] Mouse RAW264.7 cell line was incubated in DMEM complete medium and cultured in a humidified atmosphere of 37°C and 5% CO2.
[0049] 2. CCK-8 assay to detect the toxicity of the compound of formula I to RAW264.7 cells
[0050] Cells in logarithmic growth phase were taken and 3 × 10 4 / well inoculated in 96-well plates, set up drug-treated groups and blank groups, cultured for 24 hours, the drug-treated groups were added with different concentrations (10, 20, 30, 40, 50, 60, 70 μM) of compounds. After incubation for 48 hours (37°C, 5% CO2), the supernatant was discarded, 100 μL serum-free DMEM medium and 10 μL CCK-8 solution were added, incubated at 37°C, 5% CO2 for 3 hours, and the absorbance of each well was measured at 450 nm using an enzyme reader, and the determination was repeated 3 times.
[0051] 3. Elisa method to detect the release level of inflammatory factors (TNF-α, IL-6) in RAW264.7 cells
[0052] Cells in logarithmic growth phase were taken and 3×10 4Each well was inoculated in a 96-well plate and cultured in an incubator at 37°C and 5% CO2 for 24 hours. A blank group (culture medium), a model group (culture medium + 1 µg / mL LPS), a positive drug group (culture medium + 1 µg LPS + 5μM dexamethasone), and a drug group (culture medium + 1 µg LPS + 10, 20, 30μM compounds) were set up, with 4 replicates in each group. After 24 hours of continuous culture, the cell culture supernatant was aspirated, and the cell TNF-α and IL-6 release levels were detected by TNF-α and IL-6 Elisa kits, and the content was calculated according to the standard curve.
[0053] 4. Western blot analysis of protein levels in RAW264.7 cells
[0054] Western blot was used to detect the protein expression levels of inflammatory markers iNOS and COX-2 in RAW264.7 cells, as well as key proteins P65 and P-P65 in the NF-κB pathway, using GAPDH as an internal reference, and dexamethasone as a positive control.
[0055] 4.1 Cell treatment
[0056] Cells in logarithmic growth phase were taken and 3×10 4 / well were inoculated in 6-well plates. After 24 hours of incubation, drugs were administered, and blank group, model group (LPS 1 μg / mL), drug group (10, 20, 30 μM compound + LPS 1 μg / m L ), and positive drug group (dexamethasone 5 μM + LPS 1 μg / m L ) were set up and cultured for 24 hours.
[0057] 4.2 Protein extraction
[0058] After the cell culture was completed, the culture medium in the wells was discarded, the cells were washed twice with cold PBS, 150uL of RIPA lysis buffer containing protease inhibitors was added to each well (protease inhibitor: RIPA lysis buffer = 1:100), lysed for 5 min, transferred to an EP tube, and the sample was mixed with 5xSDS loading buffer (4:1), heated in boiling water for 8 min to denature the protein, centrifuged for 10 min (5000 rpm), and the supernatant was taken for later use.
[0059] 4.3 Electrophoresis
[0060] After slowly taking out the comb on the glass plate, place the plate in the electrophoresis tank, then add electrophoresis buffer to the scale, use the sample gun to load the marker and sample into each lane in sequence, insert the electrode and start electrophoresis. Perform electrophoresis at a constant voltage of 200V, and determine the appropriate electrophoresis time based on the size and position of the protein molecular weight standard band.
[0061] 4.4 Transfer
[0062] Cut PVDF membrane (activated by soaking in methanol) and filter paper to the same size as the gel, soak the PVDF membrane and filter paper in transfer solution, make a transfer clip in the order of foam, filter paper, gel, PVDF membrane, filter paper, and foam, and run at a constant current of 200 mA for 2 hours to complete the transfer.
[0063] 4.5 Closure
[0064] Use 10% skim milk diluted with 1×TBST solution as the blocking solution. After the transfer, slowly wash the PVDF membrane with 1×TBST solution, then place it in 10% skim milk and incubate it on a shaker at room temperature for 1 h.
[0065] 4.6 Incubation with primary antibody
[0066] After blocking, remove the PVDF membrane from the 10% skim milk and wash it slowly once with 1×TBST solution. Cut the PVDF membrane according to the protein molecular weight, and then soak it in the primary antibody incubation box and incubate it overnight at 4°C.
[0067] 4.7 Incubation with secondary antibody
[0068] After overnight, the PVDF membrane was removed from the primary antibody incubation box and slowly washed three times with 1× TBST solution, each time for 5 minutes. After washing, the PVDF membrane was transferred to the secondary antibody solution (1: 2000 dilution) and incubated at room temperature for 1 hour.
[0069] 4.8 Chromogenic Imaging
[0070] After the secondary antibody incubation, the PVDF membrane was removed and slowly washed three times with 1×TBST solution, each time for 10 minutes. After washing, the PVDF membrane was transferred to the ECL luminescent solution (A solution: B solution = 1:1 mixture) and fully immersed, and then placed in a dark room for exposure and imaging. Grayscale value analysis was performed using Image J software, and graph analysis was performed using Graph Pad Prism 9.
[0071] 5. Anti-inflammatory activity results
[0072] 5.1 Effect of Formula I Compound on Growth Activity of RAW264.7 Cells
[0073] In this experiment, CCK-8 method was used to detect the effect of different concentrations of compound I (0-70 μM) on cell proliferation. After 48 h of treatment, the results were as follows: Figure 2As shown, the compound of formula I has no cytotoxic activity on cells at a concentration of 0-20 μM. However, when the concentration is higher than 30 μM, the compound of formula I has a strong inhibitory effect on cell growth activity, and this effect increases with the increase of concentration.
[0074] 5.2 Effect of Formula I Compound on NO Release in RAW264.7 Cells
[0075] In this experiment, the Griess method was used to detect the level of cellular NO production and observe the effect of the compound of formula I on the amount of cellular NO release. Figure 3 As shown in the figure, compared with the blank control group, the NO release of the model group cells after LPS treatment was significantly increased (P<0.001). Compared with the model group, after adding different concentrations of the compound of formula I or the positive drug of dexamethasone, the NO release of the cells was significantly reduced, and the inhibitory effect of the compound of formula I on the production of cellular NO was enhanced with the increase of concentration. When the concentration of the compound of formula I reached 30μM, the NO release of the cells was lower than that of the positive drug group, indicating that the compound of formula I has a good inhibitory effect on the NO release of macrophages after LPS treatment.
[0076] 5.3 Effect of Formula I Compound on the Release of TNF-α and IL-6 in RAW264.7 Cells
[0077] In this experiment, Elisa method was used to detect the release of inflammatory factors TNF-α and IL-6 in cells, and the effects of different concentrations of Formula I compound on the release of TNF-α and IL-6 in cells were observed. Figure 4 As shown in the figure, the release of TNF-α and IL-6 in the blank group cells was extremely small, and the release of TNF-α and IL-6 in the model group cells treated with LPS increased significantly (P<0.001). Compared with the model group, the cells in the drug group were treated with LPS and different concentrations of the compound of formula I. The results showed that 10μM compound of formula I significantly inhibited the release of TNF-α (P<0.001) and IL-6 (P<0.001) induced by LPS; the inhibitory effect was stronger at low concentrations than at high concentrations.
[0078] 5.4 Effects of Formula I Compound on the Expression Levels of Some Proteins in RAW264.7 Cells Stimulated by LPS
[0079] In this experiment, the Western blot method was used, GAPDH was used as the internal reference, and 5 μM dexamethasone was used as the positive control to detect the effect of the compound of formula I on the expression levels of inflammatory markers iNOS, COX-2, and key proteins P65 and p-P65 in the NF-κB pathway in RAW264.7 cells. Figure 5As shown in the figure, compared with the blank group, the expression of iNOS and COX-2 in the model group cells after LPS stimulation was significantly increased (P<0.001). Compared with the model group, high concentration of Formula I compound (30μM) had a significant inhibitory effect on the expression of iNOS and COX-2 induced by LPS (P<0.001); medium concentration of Formula I compound (20μM) had a significant inhibitory effect on COX-2 (P<0.01) but no significant inhibitory effect on iNOS; low concentration of Formula I compound (10μM) had no inhibitory effect on both. In addition, as shown in the figure, LPS treatment significantly increased the phosphorylation of cellular P65 protein, while high concentration of Formula I compound treatment significantly inhibited the phosphorylation of cellular P65 protein. The above results indicate that Formula I compound may exert anti-inflammatory activity by regulating the expression level of NF-κB pathway proteins.
[0080] Test Example 2 Therapeutic effect of the compounds of the present invention on vaginal inflammation in rats
[0081] 1. Experimental methods:
[0082] The experimental rats in this case were several SPF-grade female SD rats, weighing 180-200 g. The female SD rats were randomly divided into a normal group, a model group, a metronidazole group, and low-, medium-, and high-dose groups of the compound of the present invention, with 8 rats in each group. A bacterial vaginitis model was established: all rats were adaptively fed for 1 week, and rats in all groups except the normal group were subcutaneously injected with 0.2 g of estradiol benzoate injection once a day for 7 days to put the rats in a pseudoestrus state; then, the Escherichia coli suspension was diluted to 2×10 8 ~3×10 8 cfu / mL, and 25 μL was injected into the rat vagina once a day for 7 days. The appearance of the rat vaginal opening was observed every day. When obvious congestion and swelling appeared, accompanied by a large amount of white sticky secretions, and the secretion examination results showed vigorous growth of the strain, it indicated that the rat vaginal environment had been destroyed and the bacterial vaginitis model was successfully established.
[0083] Through preliminary exploratory experiments, it was determined that the dosages of the low, medium and high dose groups of the present invention were 40, 80 and 150 mg / kg, respectively, and were administered vaginally using a syringe; the adult daily dosage of metronidazole vaginal effervescent tablets was 0.4 g, and after conversion between human and rat dosages, the dosage was determined to be 30 mg / kg, and was administered directly vaginally; rats in the normal group and the model group were given 0.32 mL / kg of normal saline vaginally, once a day, for 7 days.
[0084] 2. Index detection:
[0085] 2.1 Rats vaginal appearance scoring:
[0086] The established vaginal appearance scoring standard (Table 2) was used to score the redness, swelling and secretions of the vaginal opening of rats in each group 24 hours after the last administration of the drug. The higher the score, the more severe the vaginal inflammation of the rat.
[0087] Table 2 Scoring criteria for rat vaginal appearance
[0088]
[0089] 2.2 Rat vaginal pH detection:
[0090] 24 hours after the last administration, the pH test paper was inserted into the vaginal opening of the rats, and was quickly taken out after it was fully in contact with the vaginal secretions. The vaginal pH was compared with the standard colorimetric card and recorded.
[0091] 3. Results
[0092] 3.1 Effects of the compounds of the present invention on vaginal appearance scores in rats with bacterial vaginosis
[0093] Compared with the normal group, the vaginal swelling score and secretion score of the rats in the model group were significantly increased (P < 0.01). Compared with the model group, the above scores of the rats in each drug group were significantly reduced (P < 0.05 or P < 0.01). The results are shown in Table 3.
[0094] 3.2 Effects of the compounds of the present invention on vaginal pH in rats with bacterial vaginosis
[0095] Compared with the normal group, the vaginal pH of the rats in the model group was significantly increased (P < 0.01). Compared with the model group, the vaginal pH of the rats in each drug group (except the low-dose group of the compound of the present invention) was significantly decreased (P < 0.05 or P < 0.01).
[0096] In the vaginal opening redness and swelling scores, there were significant differences between the low-dose group and the medium-dose and high-dose groups (P<0.01); there was no significant difference between the medium-dose group and the high-dose group.
[0097] In the vaginal secretion scores, there was a significant difference between the low-dose group and the medium-dose group (P<0.01); there was a significant difference between the low-dose group and the high-dose group (P<0.05); there was no significant difference between the medium-dose group and the high-dose group.
[0098] Vaginal pH data showed that there was a significant difference between the low-dose group and the medium-dose group (P<0.05); there was no significant difference between the medium-dose group and the high-dose group.
[0099] The results are shown in Table 3.
[0100] Table 3 Comparison of vaginal appearance scores and pH values of rats in each group ( )
[0101] Group Vaginal introitus redness and swelling score Vaginal discharge score Vaginal pH Normal group 0.22 ± 0.43 0.35 ± 0.55 7.16 ± 0.25 Model Group <![CDATA[2.54 ± 0.52 a ]]> <![CDATA[2.65 ± 0.50 a ]]> <![CDATA[8.05 ± 0.43 a ]]> Metronidazole group <![CDATA[1.16 ± 0.62 b ]]> <![CDATA[0.86 ± 0.36 b ]]> <![CDATA[7.54 ± 0.33 c ]]> Low dose group <![CDATA[2.03 ± 0.55 c ]]> <![CDATA[1.74 ± 0.47 b ]]> 7.64 ± 0.34 Medium dose group <![CDATA[0.87 ± 0.65 b ]]> <![CDATA[1.04 ± 0.52 b ]]> <![CDATA[7.10 ± 0.58 b ]]> High dose group <![CDATA[1.26 ± 0.71 b ]]> <![CDATA[1.24 ± 0.45 b ]]> <![CDATA[7.14 ± 0.52 b ]]>
[0102] A: Compared with the normal group, P<0.01; B: Compared with the model group, P<0.01; C: Compared with the model group, P<0.05.
[0103] The positive drug used in the experiment is metronidazole, which is an antibiotic commonly used to treat bacterial vaginitis, but it may also cause some side effects. For example: Gastrointestinal reactions: Common ones include nausea, vomiting, loss of appetite, abdominal cramps, etc.; Nervous system symptoms: headache, dizziness, occasional paresthesia, limb numbness, ataxia, etc.; Allergic reactions: Urticaria, flushing, itching, etc. may occur in a few cases; Urinary system symptoms: such as cystitis, dysuria, etc.; Disulfiram-like reactions: Metronidazole can inhibit alcohol metabolism. During medication, alcohol and other alcoholic beverages should be avoided, otherwise it may cause facial flushing, conjunctival congestion, blurred vision, violent pulsation of blood vessels in the head and neck or pulsating headache, dizziness, nausea, vomiting, sweating, dry mouth, chest pain, myocardial infarction, acute heart failure, dyspnea, acute liver damage, and even convulsions and death and other serious reactions. The compound of the present invention is extracted from natural plants and is safer to use. Test results show that for redness and swelling of the vaginal opening, a medium dose of the compound of the present invention can achieve a good effect, and the effect is equivalent to that of the positive drug metronidazole; for vaginal secretions, compared with the model group, the high, medium and low dose groups of the compound of the present invention all achieve good efficacy, and the medium dose is the best; for the regulation of vaginal pH value, the medium and high doses of the compound of the present invention have significant differences compared with the model group, and the medium dose group of the compound of the present invention is the best administration dose.
Claims
1. A flavonoid compound, characterized in that: The structural formula is shown in Formula I: 。 2. Use of the flavonoid compound according to claim 1 in the preparation of an anti-inflammatory drug; the drug is a drug for treating bacterial vaginitis.
3. The flavonoid compound according to claim 1 is used for the preparation of Hibiscus mume, a plant of the genus Hibiscus in the family Malvaceae. Hibiscus mutabilis. Application of dried flowers or extracts of L.
4. The method for preparing flavonoid compounds according to claim 1, characterized in that: Hibiscus mutabilis Hibiscus mutabilis. The dried flowers of L are used as raw materials, extracted, separated and purified; it includes the following steps: a. Extraction: Take hibiscus flowers, grind them into powder, and extract them under reflux with 90% ethanol solution as solvent; evaporate the extract under reduced pressure to dryness to obtain dry extract; disperse and suspend the dry extract in ten times the amount of water, and then extract with equal volumes of petroleum ether, ethyl acetate and n-butanol for 3 times in sequence, evaporate the solvent to obtain three parts of extracts of petroleum ether, ethyl acetate and n-butanol respectively; b. Take the ethyl acetate extract of step a, and separate it by column chromatography using a 100-200 mesh silica gel column, using petroleum ether-ethyl acetate as the elution solvent, and eluting according to the gradient of 20:1, 8:1, 5:1, 2:1, 1:1, 1:2, 1:4, 1:10, 0:100, and collect the fractions, and receive 127 bottles in total; among them, 1-15 is Fr.A, 26-37 is Fr.B, 38-52 is Fr.C, 53-68 is Fr.D, 69-90 is Fr.E, 91-109 is Fr.F, and 110-127 is Fr.G; c. Fr.D was collected and further separated by ODS C18 medium pressure column. The eluent was methanol-water system. Gradient elution was performed according to 5:95, 10:90, 15:85, 20:80, 25:75, 30:70, 35:65, 40:60, 45:55, 50:50, 55:45, 60:40, 65:35, 70:30, 90:10, 100:
0. A total of 119 bottles of fractions were collected; among them, 1-10 was Fr.D 1, 11-13 was Fr.D 2, 14-16 was Fr.D 3, 17-20 was Fr.D 4, 21-24 was Fr.D 5, 25-26 was Fr.D 6, 27-32 was Fr.D 7, 33-38 are Fr.D 8, 39-45 are Fr.D 9, 46-48 are Fr.D 10, 49-56 are Fr.D 11, 57-68 are Fr.D 12, 69-79 are Fr.D 13, 80-96 are Fr.D 14, 97-108 are Fr.D 15, 109-119 are Fr.D 16; Fr.D5 is separated and purified by preparative liquid phase using 35% acetonitrile aqueous solution as the mobile phase to obtain the compound shown in formula I.
Citation Information
Patent Citations
Compound hibiscin as well as preparation method and application thereof
CN117003720A
Application of ramosissimone A to preparation of medicine for treating rheumatoid arthritis
CN108186625A
Method for separating flavonoids from hibiscus mutabilis based on high speed countercurrent chromatography
CN110613739A
Flavonoid compound as well as preparation method and application thereof
CN115093388A
Dyeing keratin fibers, preferably hair, comprises applying compositions containing e.g. dihydroxyflavone derivatives, manganese salts, different basifying agents or bicarbonates, and metal salt e.g. scandium and titanium, to the fibers
FR2976797A1
